Literature DB >> 24446253

VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.

Francesca Lessi1, Chiara Maria Mazzanti, Sara Tomei, Claudio Di Cristofano, Andrea Minervini, Michele Menicagli, Alessandro Apollo, Lorenzo Masieri, Paola Collecchi, Riccardo Minervini, Marco Carini, Generoso Bevilacqua.   

Abstract

Von Hipple-Lindau gene (VHL) inactivation represents the most frequent abnormality in clear cell renal cell carcinoma (ccRCC). Hypoxia-inducible factor-1α (HIF-1α) expression is regulated by O2 level. In normal O2 conditions, VHL binds HIF-1α and allows HIF-1α proteasomal degradation. A single-nucleotide polymorphism (SNP) has been found located in the oxygen-dependent degradation domain at codon 582 (C1772T, rs11549465, Pro582Ser). In hypoxia, VHL/HIF-1α interaction is abolished and HIF-1α activates target genes in the nucleus. This study analyzes the impact of genetic alterations and protein expression of VHL and the C1772T SNP of HIF-1α gene (HIF-1α) on prognosis in early-stage ccRCC (pT1a, pT1b, and pT2). Mutational analysis of the entire VHL sequence and the genotyping of HIF-1α C1772T SNP were performed together with VHL promoter methylation analysis and loss of heterozygosis (LOH) analysis at (3p25) locus. Data obtained were correlated with VHL and HIF-1α protein expression and with tumor-specific survival (TSS). VHL mutations, methylation status, and LOH were detected in 51, 11, and 12% of cases, respectively. Our results support the association between biallelic alterations and/or VHL silencing with a worse TSS. Moreover, we found a significant association between the HIF-1α C1772C genotype and a worse TSS. The same association was found when testing the presence of HIF-1α protein in the nucleus. Our results highlight the role of VHL/HIF-1α pathway in RCC and support the molecular heterogeneity of early-stage ccRCC. More important, we show the involvement of HIF-1α C1772T SNP in ccRCC progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24446253     DOI: 10.1007/s12032-014-0840-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma.

Authors:  Vincenzo Ficarra; Luigi Schips; François Guillè; Guorong Li; Alexandre De La Taille; Tommaso Prayer Galetti; Luca Cindolo; Giacomo Novara; Richard E Zigeuner; Emiliano Bratti; Jacques Tostain; Vincenzo Altieri; Claude C Abbou; Walter Artibani; Jean-Jacques Patard
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

2.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

3.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Authors:  Jung Han Kim; Chul Won Jung; Yeon Hee Cho; Jeeyun Lee; Se-Hoon Lee; Ho Young Kim; Jinny Park; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

4.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.

Authors:  H Brauch; G Weirich; J Brieger; D Glavac; H Rödl; M Eichinger; M Feurer; E Weidt; C Puranakanitstha; C Neuhaus; S Pomer; W Brenner; P Schirmacher; S Störkel; M Rotter; A Masera; N Gugeler; H J Decker
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

Review 5.  The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis.

Authors:  Xin Hu; Yuan Fang; Jun Zheng; Yazhou He; Xin Zan; Sen Lin; Xi Li; Hao Li; Chao You
Journal:  Tumour Biol       Date:  2013-09-18

6.  Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

Review 7.  Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

Authors:  W Marston Linehan; James Vasselli; Ramaprasad Srinivasan; McClellan M Walther; Maria Merino; Peter Choyke; Cathy Vocke; Laura Schmidt; Jennifer S Isaacs; Gladys Glenn; Jorge Toro; Berton Zbar; Donald Bottaro; Len Neckers
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.

Authors:  Farkas Sükösd; Naoto Kuroda; Tamas Beothe; Amrit Pal Kaur; Gyula Kovacs
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

9.  The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer.

Authors:  Hye Ok Kim; Yong Hwa Jo; Juhie Lee; Sang Sook Lee; Kyung-Sik Yoon
Journal:  Oncol Rep       Date:  2008-11       Impact factor: 3.906

10.  A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation.

Authors:  Melanie J Percy; Sharon M Mooney; Mary Frances McMullin; Adrian Flores; Terence R J Lappin; Frank S Lee
Journal:  Mol Cancer       Date:  2003-09-09       Impact factor: 27.401

View more
  14 in total

1.  Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.

Authors:  Shuigen Zhou; Longxin Wang; Guimei Li; Zhengyu Zhang; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas.

Authors:  Longxin Wang; Haibing Hu; Feng Tian; Wenquan Zhou; Shuigen Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.

Authors:  Cai Lv; Zhiming Bai; Zhenxiang Liu; Pengcheng Luo; Jie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas.

Authors:  Xiaolin Wang; Yushan Liu; Guangxin Cao; Xueliang Zhang; Haifei Xu; Hanfeng Xu; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway.

Authors:  Bin Song; Ying Shu; Tianlei Cui; Ping Fu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 6.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

7.  Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.

Authors:  Ying-Li Lin; Yun-Peng Wang; Hong-Zhao Li; Xu Zhang
Journal:  Med Sci Monit       Date:  2017-07-08

8.  Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Authors:  Ying-Li Lin; Shi-Liang Gui; Hong Guo; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2015-09-25

9.  Hypoxia inducible factor-1 alpha and prolinhydroxlase 2 polymorphisms in patients with severe sepsis: a prospective observational trial.

Authors:  Annika Höcker; Miriam Rabeling; Alexandra Bick; Linda Cox; Maximiliane Kreuzer; Andrea Engler; Kai Walstein; Hagen S Bachmann; Karl-Heinz Jöckel; Lewin Eisele; Michael Adamzik; Jürgen Peters; Simon T Schäfer
Journal:  BMC Anesthesiol       Date:  2016-08-11       Impact factor: 2.217

10.  Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.

Authors:  Wenjin Xi; Xu Chen; Jinbo Sun; Wei Wang; Yi Huo; Guoxu Zheng; Jieheng Wu; Yufang Li; Angang Yang; Tao Wang
Journal:  Med Sci Monit       Date:  2018-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.